Long-acting diabetes med Bydureon passed a crucial test of its effects on heart rhythms, said the drug’s developers Amylin, Eli Lilly and Alkermes. One analyst said the results may help the drug right ...
In clinical trials, treatment with Bydureon BCise resulted in average HbA1c reductions of up to 1.4% and average weight loss of up to 3.1 pounds when used as monotherapy or as an add-on to metormin, a ...
SAN DIEGO & INDIANAPOLIS & WALTHAM, Mass.--(BUSINESS WIRE)-- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced results ...
BYDUREON BCISE The expanded approval was based on data from a phase 3 study that evaluated exenatide extended-release in 82 patients aged 10 to 17 years with type 2 diabetes. The Food and Drug ...
European Union regulators have approved the first once-per-week diabetes medication, the companies that developed the drug said Tuesday. Indianapolis-based Eli Lilly and Co., San Diego-based Amylin ...
BYDUREON is a once-weekly formulation of exenatide, the active ingredient in BYETTA. BYETTA has been available in the U.S. since June 2005 and is used in more than 60 countries worldwide to improve ...
SAN DIEGO--(BUSINESS WIRE)-- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced results from long-term extensions of the ...
AstraZeneca (NYSE: AZN) announced that the FDA has approved Bydureon (exenatide extended-release) for injectable suspension as an add-on therapy to basal insulin in adults with type 2 diabetes with ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the US Food and Drug Administration (FDA) has approved BYDUREON ® (exenatide extended-release) for injectable suspension as an add-on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback